Tabuk Pharmaceutical Manufacturing Company Sustainability Profile
Tabuk Pharmaceutical Manufacturing Company, commonly referred to as Tabuk Pharma, is a leading player in the pharmaceutical industry, headquartered in Saudi Arabia. Established in 1994, the company has made significant strides in the Middle East and North Africa (MENA) region, focusing on the development, manufacturing, and marketing of high-quality pharmaceutical products. Tabuk Pharma offers a diverse range of core products, including prescription medications, over-the-counter drugs, and specialised formulations, distinguished by their commitment to innovation and quality. The company has achieved notable milestones, positioning itself as a trusted name in healthcare, with a strong market presence and a reputation for excellence in pharmaceutical manufacturing.
DitchCarbon Score
How does Tabuk Pharmaceutical Manufacturing Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tabuk Pharmaceutical Manufacturing Company's score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tabuk Pharmaceutical Manufacturing Company, headquartered in Saudi Arabia, has made significant commitments towards achieving net-zero carbon emissions. Although specific emissions data for the most recent year is not available, the company has set ambitious long-term targets through the Science Based Targets initiative (SBTi). These targets aim for net-zero emissions across all scopes by 2050, with a commitment initiated in 2023. As a current subsidiary of Astra Industrial Group Company, Tabuk Pharmaceuticals' climate initiatives are aligned with broader corporate sustainability goals. The company is actively working towards reducing its carbon footprint, although specific reduction percentages have not been disclosed. Tabuk Pharmaceuticals is committed to transparency and accountability in its climate actions, reflecting a growing trend within the pharmaceutical sector to address climate change proactively. The company's net-zero commitment underscores its dedication to sustainable practices and environmental stewardship in the pharmaceutical, biotechnology, and life sciences industries.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Tabuk Pharmaceutical Manufacturing Company's Industry?
How Carbon Intensive is Tabuk Pharmaceutical Manufacturing Company's Location?
Tabuk Pharmaceutical Manufacturing Company's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Tabuk Pharmaceutical Manufacturing Company has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
